Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry

The gene encoding MUM1 was characterized as a possible translocation partner in chromosomal abnormalities involving a significant number of multiple myelomas. The overexpression of the MUM1 protein as a result of translocation t(6;14) (p25;q32) identified MUM1 as a putative regulatory molecule involved in B-cell differentiation and tumorigenesis. The expression of MUM1 protein in multiple myelomas supports this hypothesis. In the current study, using tissue microarray technology, we have tested the expression of the MUM1 protein in 1335 human malignancies and normal tissues. Our data show that the MUM1 protein is expressed in a wide spectrum of hematolymphoid neoplasms and in malignant melanomas but is absent in other human tumors. In addition, in tissue microarrays as well as in conventional paraffin sections, MUM1 staining was found to lack specificity in detecting plasmacytic differentiation as compared with two markers, CD138/Syndecan and VS38, commonly used in paraffin immunohistochemistry for detection of plasma cells.

[1]  D. Carey.  SYNDECANS: MULTIFUNCTIONAL CELLSURFACE CO-RECEPTOR , 1997 .

[2]  K. Mayne,et al.  VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. , 1994, Journal of clinical pathology.

[3]  K. Offit,et al.  BCL-6 protein is expressed in germinal-center B cells. , 1995, Blood.

[4]  T. Taniguchi,et al.  A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes , 1996, Molecular and cellular biology.

[5]  R. Sanderson,et al.  B lymphocytes express and lose syndecan at specific stages of differentiation. , 1989, Cell regulation.

[6]  H. Larjava,et al.  Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. , 1994, European journal of cell biology.

[7]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[9]  J. Gala,et al.  A panel of antibodies for the immunostaining of Bouin's fixed bone marrow trephine biopsies. , 1997, Journal of clinical pathology.

[10]  R. Iozzo,et al.  Cell surface heparan sulfate proteoglycan and the neoplastic phenotype , 1988, Journal of cellular biochemistry.

[11]  R. Warnke,et al.  Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  L. Kjellén,et al.  Proteoglycans: structures and interactions. , 1991, Annual review of biochemistry.

[13]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[14]  S. Pileri,et al.  Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. , 1996, Blood.

[15]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[16]  M. Hall.  Get together , 1985, Nature.

[17]  I. Kovalszky,et al.  Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. , 1997, European journal of cancer.

[18]  S. Horning,et al.  Follicular large-cell lymphoma: intermediate or low grade? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Taniwaki,et al.  Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. , 1994, Blood.

[20]  I. Hanamura,et al.  MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies , 2000, Leukemia.

[21]  T. Taniguchi,et al.  Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.

[22]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[23]  T. Therneau,et al.  Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. , 1998, Leukemia & lymphoma.

[24]  A. Brass,et al.  Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. , 1996, Genes & development.

[25]  T. Mak,et al.  Cooperative interaction between the DNA-binding domains of PU.1 and IRF4. , 1998, Journal of molecular biology.

[26]  L. Larocca,et al.  Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 1998, Blood.

[27]  M. Mayes,et al.  Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryo. , 1991, Development.

[28]  L. Staudt,et al.  BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major. , 1999, Journal of immunology.

[29]  T. Mak,et al.  Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. , 1996, Genomics.

[30]  J. Woodliff,et al.  Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen , 1993 .

[31]  U. Storb,et al.  Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. , 1995, Genes & development.

[32]  B. Klein,et al.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.

[33]  T. Mak,et al.  Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.

[34]  M. Gordon,et al.  Hierarchical organization of hematopoietic microenvironments: role of proteoglycans. , 1988, Leukemia.

[35]  G. Gaidano,et al.  Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. , 1997, Blood.

[36]  B. Barlogie,et al.  Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. , 1998, Blood.

[37]  J. Shanks,et al.  VS38 immunostaining in melanocytic lesions. , 1996, Journal of clinical pathology.

[38]  A. Chott,et al.  Expression of VS38 in osteoblasts and stroma cells of bone tumors. , 1997, Pathology, research and practice.

[39]  L. Berczi,et al.  Syndecan‐1 (CD138) expression in human non‐Hodgkin lymphomas , 1999, British journal of haematology.

[40]  S. Franceschi,et al.  Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. , 1998, Blood.

[41]  H Stein,et al.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  A. Banham,et al.  The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. , 1997, Journal of clinical pathology.

[43]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[44]  J. Perkel,et al.  A two-step mechanism for recruitment of Pip by PU.1. , 1998, Journal of immunology.

[45]  R. Warnke,et al.  Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. , 1986, American journal of clinical pathology.

[46]  H Stein,et al.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.

[47]  L. Glimcher,et al.  Transcription Factors in Lymphocyte Development— T and B Cells Get Together , 1999, Cell.

[48]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[49]  A. Pinto,et al.  Characterization of anti‐CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan‐1 in human lymphoma cells , 1999, British journal of haematology.